Does Aurobindo also plan to launch its COVID vaccine in India?
Answer
Answer
Aurobindo Pharma based out of Hyderabad and US based Covaxx have inked an exclusive licence agreement to develop, commercialise and manufacture UB-612. This is the first Multitope Peptide-based vaccine to fight COVID-19. Currently Phase 1 clinical trials are on.
Aurobindo Pharma will get the exclusive rights to develop, manufacture and sell the UB-612 vaccine in India and also to UNICEF. In addition, Aurobindo also gets the non-exclusive rights to make and sell in other select emerging and developing economies in the world.